Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these patients.
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Use of Minimal
Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these patients.
Patients and Methods
Analysis included 3,113 patients who were treated in the Medical Research Council UKALL2003 multicenter randomized trial (NCT00222612) between 2003 and 2011. MRD was measured by using standardized real-time quantitative PCR. Median follow-up was 5 years 9 months.
Results
Fifty-nine patients (1.9%) had morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0) and 5-year overall survival of 57.7% (95% CI, 44.2 to 71.2). Of these, a small proportion of patients with M2 marrow (6 of 44) and a low EOI MRD level (, 0.01%) had 5-year EFS of 100%. Conversely, among patients with morphologic remission 2.3% (61 of 2,633) had high MRD ($ 5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar to those with morphologic induction failure. Redefining induction failure to include morphologic induction failure and/or MRD $ 5% identified 3.9% (120 of 3,133 patients) of the trial cohort with 5-year EFS of 48.0% (95% CI, 39.3 to 58.6). Induction failure (morphologic or MRD $ 5%) occurred most frequently in T-ALL (10.1%; 39 of 386 T-ALL cases) and B-other ALL, that is, lacking established chromosomal abnormalities (5.6%; 43 of 772 B-other cases). Genetic testing within the B-other group revealed the presence of PDGFRB gene fusions, particularly EBF1-PDGFRB, in almost one third of B-other ALL cases.
Conclusion
Integration of EOI MRD level with morphology identifies induction failure more precisely than morphology alone. Prevalence of EBF1-PDGFRB fusions in this group highlights the importance of genetic screening to identify abnormalities that may be targets for novel agents.
INTRODUCTION
Overall survival in children with acute lymphoblastic leukemia (ALL) who are treated with contemporary regimens is now . 90%. 1 Whereas the vast majority of patients experience rapid response to chemotherapy, a minority do not achieve morphologic remission by the end of induction (EOI). A recent international analysis of induction failure (IF) demonstrated that, although most patients do eventually achieve a remission, long-term outcome is poor 2 ; however, these data were based on historical cases that were treated between 1985 and 2000, and the outcome of IF in contemporary protocols has not been examined in detail.
Of importance, the previous analysis predates the era of minimal residual disease (MRD) monitoring, which is now considered the most important prognostic factor in pediatric ALL. 3, 4 Studies in pediatric acute myeloid leukemia have demonstrated flow cytometry-based MRD to be more accurate than morphology in defining complete remission 5, 6 ; however, at present, the role of MRD in defining and stratifying IF in pediatric ALL remains unknown. Furthermore, although it is known that IF is increased in those patients with high-risk chromosomal abnormalities, 2 the role of newly described ABLclass and Janus kinase (JAK)-signal transducers and activators of transcription (STAT) genetic abnormalities 7 has not been fully explored. Identification of such lesions could provide an opportunity for the use of targeted therapy in this high-risk group.
To address these issues, we analyzed all cases of morphologic IF in the recently reported large, multicenter, randomized controlled trial, Medical Research Council UK ALL 2003 (MRC  UKALL 2003 ). In addition, we investigated whether EOI MRD should be incorporated into the definition of IF and whether a targeted genetic screening strategy identifies patients with lesions that are amenable to treatment with novel agents.
PATIENTS AND METHODS
Participants and Trial Protocol
This study included all patients who were enrolled in the MRC UKALL 2003 trial, as previously reported. 4, 8 An overview of the protocol, including treatment regimens (Appendix Table A1 , online only), can be found in the Appendix (online only).
MRD Assessment
Bone marrow MRD was measured within five laboratories in the United Kingdom using standardized real-time quantitative PCR for immunoglobulin and T-cell receptor antigen gene rearrangements.
9 Quantitative range was 0.01%. An exact MRD cutoff of 0.01% was used to stratify patients.
Definitions
IF was defined as failure to achieve morphologic complete remission (, 5% bone marrow blasts) at EOI or persistent extramedullary disease. Patients with M2 marrow (5% to 25% blasts) were allocated to the highrisk arm, regimen C. Patients with M3 marrow (. 25% blasts) were deemed to have experienced treatment failure and were taken off protocol, although this was not defined as an event for the purpose of survival analyses. Microscopic assessments of marrow were done locally with no central review.
Genetic Analysis
Cytogenetic analysis, including fluorescence in situ hybridization (FISH) for detection of chromosomal abnormalities of prognostic significance, was carried out in the regional cytogenetics laboratories as part of routine diagnosis but was reviewed and collated by the Leukaemia Research Cytogenetics Group, as previously described. 10 A representative cohort of patients with B-other ALL-those cases lacking established chromosomal abnormalities-were screened for rearrangements that involved ABL1, ABL2, PDGFRB, CSF1R, CRLF2, and JAK2 by using commercially available or home-grown 7,11 break-apart FISH probes (Cytocell, Cambridge, UK; Leica Microsystems, Milton Keynes, UK) or, in the case of P2RY8-CRLF2, by using multiplex ligation-dependent probe amplification (SALSA MLPA kit P335 IKZF1; MRC, Holland, the Netherlands).
12 EBF1-PDGFRB fusion was confirmed and validated by FISH and RT-PCR as recently described.
13
Statistical Analysis
Categorical variables were compared with standard x 2 tests or Fisher's exact tests as appropriate. Time-to-event outcomes were defined from start of treatment. Event-free survival (EFS) was the primary end point and was defined as time to relapse, secondary tumor, or death. Overall survival (OS) was time to death. Kaplan-Meier curves were produced and compared with the log-rank method. Multivariable analysis used Cox proportional hazards regression models to test whether effects of prognostic factors were independent, with tests of proportional hazards using an interaction with time variable for significant factors. Graphs were plotted to 8 years to show as much information as possible; data presented in the text relate to 5-year outcome. All P values were two-sided. Linear trend P values were presented for variables with a natural ordering, such as white blood cell count (WCC), on the basis of suitable tests with one degree of freedom, for example, Mantel-Haenszel x 2 , log-rank test for trend. Statistical analyses were performed in SAS (SAS/STAT User's Guide, Version 9.3; SAS Institute, Cary, NC) or with in-house programs. Figures were created with R (version 3.0.1; The R Foundation, Vienna, Austria). Median follow-up was 5 years 9 months (range, 1 month to 10 years 1 month).
RESULTS
Patient Characteristics
Of 3,207 patients registered for the trial, 3,113 were included in this analysis after exclusion of those with Philadelphia-positive ALL, withdrawal of consent, or misdiagnosis (Fig 1) . Patient characteristics are listed in Table 1 .
Fifty-nine patients ( (n = 3) (n = 14) (n = 7) (n = 70) Fig 2) , although this was not significant, likely as a result of the small number of cases.
The majority of patients with IF (51 of 59; 86%) did eventually achieve remission. Patients with M2 marrow were escalated to regimen C and 40 of 44 achieved complete remission (CR) after consolidation therapy. The majority of patients with M2 marrow who achieved CR continued on regimen C, whereas those who failed to achieve remission were treated off protocol, as were those with M3 marrow (Appendix Table A2 , online only). Seventeen patients with IF (10 M2, 7 M3) underwent hematopoietic stem cell transplantation in their first remission (6 matched related donor, 9 matched unrelated donor, 1 not known). The 5-year EFS in these patients was 41.2% (95% CI, 18.6 to 62.6) compared with 55.9% (95% CI, 39.3 to 29.6; P = .627) for those patients with M2 and M3 marrows who did not undergo hematopoietic stem cell transplantation in CR1. IF was associated with several high-risk characteristics, including age, WCC, T-cell phenotype, and high-risk cytogenetic subgroups (Table 1) . IF was particularly frequent in older patients; 6.6% of patients age $ 16 years experienced IF compared with 0.9% in those age , 10 years and 3.8% in those age 10 to 15 years (P trend , .0001). In addition, patients with Down's syndrome were at greater risk of IF (5.7% v 1.8%; P = .005).
Several factors seem to influence outcome after IF ( 
MRD and IF
Because MRD is the strongest predictor of outcome in pediatric ALL and as MRD was the only treatment response factor that was independently related to EFS in our patients with M2 and M3 marrows, we explored the role of MRD assessment in stratifying those with morphologic IF. MRD data were available in 45 (76%) of 59 cases; of cases without MRD, most were T-ALL (10 of 14). These data identified a minority of patients (n = 6; Fig 3) with M2 marrows but MRD , 0.01% who had a 5-year EFS of 100% (Table 2) .
We next compared EOI MRD in patients with M2 and M3 marrows with patients in complete morphologic remission (M1 marrow). MRD levels were highly variable, including in a small group of patients (54 of 2,349; 2.3%) with M1 marrows and high MRD levels ($ 5%), which suggested IF despite morphologic remission (Fig 3 and Appendix Tables A3 and A4, online High MRD ($ 5%) in the context of morphologic remission was particularly common in patients with T-ALL (8.0%; 22 of 276 patients with T-ALL with MRD available) compared with patients with B-precursor ALL (1.5%; 36 of 2,357; P , .001). As previously described, patients with EOI MRD $ 0.01% were randomly assigned to either continue their initial regimen (A/B) or move to the more intensive regimen C. Patients with MRD $ 5% who were treated with regimen C had a better outcome than did those who were treated with regimen A/B, which suggests that intensified treatment may be beneficial, although this difference was not significant Given the over-representation of B-other ALL within the IF group, we screened 44 of 52 cases with B-other ALL or unknown failed cytogenetic cases for one or more of ABL-class and/or JAK-STAT rearrangements that involve ABL1, ABL2, PDGFRB, CSF1R, CRLF2, and JAK2. These 44 patients were representative of the 52 patients with B-other ALL or failed cytogenetics in terms of sex, age, WCC, and survival.
We did not detect any patients with IF who harbored a gene fusion that involved CSF1R (0 of 36) or JAK2 (0 of 35). Two patients had an ABL1 (1 of 33) or ABL2 (1 of 23) fusion; however, 11 (31%) of 36 patients with B-other with IF had a rearrangement that involved the PDGFRB gene, which was significantly more frequent than among the remaining B-other cases (3 of 224; 1.3%; P , .001). In 9 of 11 patients, rearrangement was confirmed to be EBF1-PDGFRB fusion, 12 whereas one case had ATF7IP-PDGFRB. The remaining case did not involve EBF1, and insufficient material was available for further analysis. Patients with EBF1-PDGFRB fusions have been shown to respond to targeted therapy with imatinib, which provides a potential treatment in these high-risk patients.
14,15
Among 38 B-other patients with IF, a total of four (11%) harbored a CRLF2 rearrangement (PR2Y8-CRLF2, n = 3; and IGH-CRLF2, n = 1). Frequencies of PR2Y8-CRLF2 (approximately 10%) and IGH-CRLF2 (approximately 3%) among patients with B-other ALL with IF are comparable to those observed in our previous studies.
12,16
Because IF has previously been associated with the early T-precursor (ETP) ALL Tables A4 and A7 , online only). Of importance, this subgroup of ETP-ALL with MRD $ 5% had a 5-year EFS of 50.0% (95% CI, 1.0 to 99.0) compared with 92.3% (95% CI, 77.8 to 100.0) for patients with ETP-ALL with MRD , 5% (P = .05).
DISCUSSION
If outcomes in pediatric ALL are to further improve, stratification must accurately identify patients with high-risk disease who require intensification of therapy while sparing the majority of patients from potentially toxic treatment. Treatment response that uses morphology or MRD has formed an integral part of stratification in recent trials and has been shown to effectively riskstratify patients, with those with morphologic IF among those with poorest outcome. Disappointingly, despite improvements in overall outcome in pediatric ALL, our study demonstrates that there has been little advance in the treatment of children with IF. MRD has now been established as the most powerful factor in predicting outcome in pediatric ALL. Our study adds to this evidence by demonstrating the value of MRD assessment in the context of morphologic IF. By using MRD assessment, we identified a small subgroup of patients within the IF group who had low MRD levels. Crucially, these patients had an excellent outcome, with 5-year EFS of 100%. Without central review, the accuracy of M2 status cannot be assured in these six cases and may explain the nonconcordance of morphologic and MRD levels. Although this only affects a small number of cases, integration of MRD results could potentially spare these patients the toxicity of more intensive therapy.
Furthermore, whereas the majority of studies use low MRD values to guide treatment stratification, our study shows that high MRD levels can be effectively used to identify patients with an extremely poor outcome. It is important to note that the realtime quantitative PCR method that was used for MRD measurement is designed to optimally detect disease between 0.01% and 1% and may therefore not give an exact measurement of disease at higher levels. However, our data clearly show that those patients with morphologic remission, but high EOI MRD ($ 5%), have outcomes similar to patients with morphologic IF. Overall, this suggests that MRD measurement provides a more reliable assessment of disease response than morphology, as previously described in pediatric acute myeloid leukemia. 5, 6, 20 Do these data indicate that treatment response in ALL should be based solely on MRD assessment? High levels of MRD certainly select a poor risk population in the context of morphologic remission. Conversely, those with morphologic IF and MRD , 5% have a relatively good outcome (Table 2) , which suggests that remission status could be based solely on MRD level. However, given the relatively small number of cases and the fact that outcomes are likely dependent on treatment and MRD technique used, our data must be confirmed in other cohorts before we can abandon morphologic assessment altogether. This question will therefore be the subject of a forthcoming international analysis by the Ponte di Legno working group.
In light of our results, within the United Kingdom group, we have amended the current protocol to redefine IF as EOI MRD $ 5% and/or M3 marrow. Those patients with M2 marrow without an EOI MRD result will have morphology assessed by central review. Given the extremely poor outcome in this population, it is essential that these patients be accurately identified so that they can be considered for early treatment intensification and use of novel agents.
Results of the cytogenetic screening are therefore significant, identifying EBF1-PDGFRB rearrangements in approximately 10% of patients with IF. This result is particularly interesting given reports of the effectiveness of ABL tyrosine kinase inhibitors, such as imatinib, in the treatment of children with refractory ALL that harbors ABL-class fusions.
14,15 Early intervention in these patients led to CR and long-term survival, which highlights the importance of identifying targetable lesions early in therapy.
Despite making up only 12.5% of patients in the trial, 32% of IF occurred in T-ALL. Even so, our analysis suggests that approximately one quarter of these cases may be a result of ETP-ALL and that MRD $ 5% identifies a subgroup of ETP-ALL with a poor outcome, full immunophenotyping and MRD results were not available in all T-ALL patients and these data require confirmation in other cohorts. However, importantly, previous studies have shown that ETP-ALL is frequently associated with an absence of molecular markers for MRD assessment, 18,19 which means that PCR-based MRD detection may fail to identify high-risk patients. Flow-based MRD assessment should therefore be considered in all patients with ETP-ALL. Whereas ETP-ALL accounts for a subgroup of these patients, the other mechanisms that drive IF in T-ALL remain largely unknown and detailed genetic characterization of the T-ALL subgroup is urgently needed. Furthermore, as the complexity of genetic characterization of pediatric ALL increases, individual genetic subgroups will contain smaller patient numbers, underlining the need for collaborative international trials that are adequately powered to test new therapies in these high-risk patients.
Given the enrichment of PDGFRB fusions in IF and the potential for targeted therapy, the United Kingdom group has adopted a targeted molecular screening strategy directed at highrisk patients (Appendix Fig A2, online only) . Therefore, any patient on the current UKALL 2011 trial with B-other or T-ALL with EOI MRD . 1% will undergo screening for ABL-class fusions. Patients with targetable lesions will be considered for treatment with novel agents.
Overall, our results suggest that MRD provides a more objective measure of IF than morphology. Of importance, combining patients who fail to achieve a morphologic remission with those with MRD $ 5% selected almost 4% of trial entrants, which suggests that IF is more common than previously reported. This strategy allows identification of a subgroup of patients with extremely poor outcome with conventional treatment. As a result of this study, the United Kingdom trials group has revised the definition of IF and implemented a new screening algorithm to identify targetable lesions in an attempt to improve outcomes in this high-risk group. 
